Conduit Pharma Intends To Change Its Name To CDT Equity Inc.

• Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships and out-licensing

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announce that it intends to change its name to CDT Equity Inc. ("CDT") reflecting the evolution of its strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.

CDT's strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies despite strong Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facility, we aim to improve drug properties and have successfully extended patent life of certain drugs by up to 20 years. Our current pipeline includes candidates targeting inflammatory and autoimmune disorders, as well as idiopathic male infertility, dermatology and animal health.

Our collaboration with Sarborg enables CDT to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel repurposing opportunities against a database of over 800 disease signatures. Sarborg's insights have directly informed two new combination patent filings, strengthening our intellectual property portfolio. In addition, CDT has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention. CDT look to progress out-licensing opportunities based on this data, if these trials are successful.

A further partnership with Manoira enables CDT to expand the scope of its drug portfolio into the animal health market in a cost-efficient manner. This collaboration allows CDT to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating for human applications. This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market.

Repositioning CDT enables the company to explore multiple opportunities in the healthcare, biotech and broader technology innovation. The Board of CDT continue to evaluate a cryptocurrency treasury reserve strategy, working with consultants to best advise a novel market which has seen significant recent activity and success for respective stakeholders. Long-term exposure to digital assets can present both strategic and financial benefits as part of a diversified capital management approach.